The Journal of clinical psychiatry
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.
We report the results from a multicenter, double-blind, randomized, fixed-dose study designed to evaluate the relationship between daily dose and efficacy of adinazolam-SR in patients with panic disorder with agoraphobia. ⋯ These results suggest that adinazolam-SR at doses of 60-mg/day or greater administered twice daily is a safe and effective treatment in selected patients with panic disorder with agoraphobia.